LogicBio Therapeutics Q4 2023 Earnings Report

LogicBio Therapeutics EPS Results

• Actual EPS: -$2.82
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

LogicBio Therapeutics Revenue Results

• Actual Revenue: $53.00 million
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

LogicBio Therapeutics Announcement Details

• Quarter: Q4 2023
• Date: 3/4/2024
• Time: N/A
• Conference Call Date: Tuesday, March 5, 2024
• Conference Call Time: 7:00AM ET

LogicBio Therapeutics (NASDAQ:LOGC), a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company's GeneRide technology is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid; and gene delivery platform, sAAVy is an adeno-associated virus, which is designed to optimize gene delivery for treatments in a range of indications and tissues. Its lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia. The company has a collaboration with Children's Medical Research Institute to develop next-generation capsids for gene therapy and gene editing applications in the liver, as well as additional tissues; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop LB-301, an investigational therapy for the treatment of Crigler-Najjar syndrome. The company also has a research collaboration, license, and option agreement with CANbridge Care Pharma Hong Kong Limited; and collaboration agreement with Daiichi Sankyo Company. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts.